Morgan Stanley Sticks to Its Buy Rating for Xero Limited (XROLF)
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, McLeod is a 3-star analyst with an average return of 2.7% and a 53.69% success rate. McLeod covers the Communication Services sector, focusing on stocks such as News Corp, News Corporation Shs B Chess Depository Interests repr 1 Sh, and REA Group Ltd.
In addition to Morgan Stanley, Xero Limited also received a Buy from UBS's Phil Campbell in a report issued today. However, yesterday, Jefferies maintained a Hold rating on Xero Limited (Other OTC: XROLF).
XROLF market cap is currently $19.38B and has a P/E ratio of 134.72.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Microsoft Flexes AI and Cloud Strength: Is MSFT Stock a Buy Here?
Microsoft (MSFT) delivered stronger-than-expected fiscal fourth-quarter financials, getting a boost from the solid demand for its cloud computing services and its artificial intelligence (AI) offerings. The market responded swiftly to the upbeat earnings, with MSFT shares jumping more than 8% in the pre-market session. Microsoft's strong financials show that the tech giant has strengthened its competitive positioning in two of the fastest-growing areas in techA. It has built a comprehensive AI tech stack that spans infrastructure, tools, and applications. On the cloud front, Azure continues to grow, strengthening Microsoft's leadership in enterprise IT as more organizations shift to digital-first strategies. More News from Barchart Morgan Stanley Says Nvidia Has 'Exceptional' Strength. Should You Buy NVDA Stock Here? Dear MicroStrategy Stock Fans, Mark Your Calendars for July 31 2 Growth Stocks Wall Street Predicts Will Soar 74% to 159% Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! The positives are reflected in MSFT stock. Notably, Microsoft stock has witnessed a strong run, rallying sharply over the past three months. While its valuation is undoubtedly less of a bargain after the recent run-up, Microsoft's long-term growth outlook remains compelling. Microsoft is benefiting from current AI and cloud demand and also laying the groundwork for sustained future growth. Its large backlog of enterprise contracts points to a steady stream of recurring revenue, while its AI tools are quickly becoming essential for businesses looking to improve productivity and modernize their operations. The solid demand environment and the tech giant's significant capital investments suggest that the rally in MSFT stock is far from over. Microsoft to Maintain Its Upward Trajectory Microsoft delivered record-breaking fourth-quarter results, driven by surging demand for its cloud and AI services. Microsoft's commercial bookings surpassed the $100 billion mark, up 37% from the prior year. This growth was powered by strong performance in long-term cloud contracts, including a significant increase in $10 million and $100 million-plus deals for both Azure and Microsoft 365. Cloud remains the centerpiece of Microsoft's growth story. Total cloud revenue reached $46.7 billion for the quarter, growing 27% year-over-year. Microsoft's Productivity and Business Processes segment also performed strongly, generating $33.1 billion in revenue, an increase of 16%. That growth was fueled by both commercial and consumer cloud products under the M365 umbrella. M365 commercial cloud revenue rose 18%, topping internal forecasts. Average revenue per user (ARPU) continues to benefit from the adoption of premium offerings like E5 and the AI-powered M365 Copilot. Microsoft also saw a 6% year-over-year increase in paid commercial seats, with expansion especially strong among small to mid-sized businesses and frontline workers. Looking ahead to the first quarter, Microsoft expects M365 commercial cloud growth to land between 13% and 14% in constant currency, with ARPU growth again supported by premium tier adoption and AI tools. On the consumer side, M365 cloud revenue grew 20%, driven by both subscriber growth (up 8%) and higher ARPU following a recent price increase. The company anticipates continued momentum, projecting low-twenties percentage growth in the coming quarter. The Intelligent Cloud segment, which includes Azure, saw revenue climb to $29.9 billion, a 26% increase. Azure itself grew revenue 39%, thanks to strong demand from large enterprise customers for core infrastructure services. While Microsoft is steadily adding data center capacity to meet demand, the appetite for Azure's AI and cloud capabilities still exceeds available supply. Looking ahead, Microsoft projects Intelligent Cloud revenue of $30.1 to $30.4 billion in Q1, with Azure expected to grow around 37% in constant currency. Continued strength in demand for Microsoft's comprehensive cloud portfolio positions Azure to remain a key driver of growth. Wall Street Recommends a 'Strong Buy' on MSFT Stock Wall Street analysts remain bullish on Microsoft, with a consensus rating of 'Strong Buy.' While the Street has an average price target of $561.35 on MSFT stock, the latest earnings beat and positive guidance suggest that analysts will revise their price targets upward. In short, Microsoft's AI and cloud momentum provide a solid foundation for durable growth. With strong fundamentals, expanding enterprise adoption, and significant scale, Microsoft appears well-positioned to maintain its upward trajectory. While the stock may not be cheap, MSFT still looks like a solid bet. On the date of publication, Amit Singh did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
an hour ago
- Yahoo
Here's when the economic data may start showing the tariff impact
The US economy will undoubtedly feel the impact of President Trump's tariffs. But when might it start showing up in the data? Morgan Stanley chief global economist Seth Carpenter took a closer look to get a rough idea. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts. Related Videos US GDP Grows by 3% in Second Quarter IMF's Gourinchas Says Tariffs Causing Tepid Growth Job openings data falls short of estimates Tariff deadline, jobs report, Exxon earnings: What to Watch Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Is Wall Street Bullish or Bearish on Bristol-Myers Stock?
Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) is a leading biopharmaceutical company that discovers, develops, licenses, manufactures, markets, and sells innovative medicines across several therapeutic areas. Valued at a market cap of $93.6 billion, the company offers products for oncology, haematology, immunology, cardiovascular, and neuroscience, among others. This healthcare giant has lagged behind the broader market over the past 52 weeks. Shares of BMY have declined 6.3% over this time frame, while the broader S&P 500 Index ($SPX) has soared 17%. Moreover, on a YTD basis, the stock is down 18.7%, compared to SPX's 8.2% gain. More News from Barchart Morgan Stanley Says Nvidia Has 'Exceptional' Strength. Should You Buy NVDA Stock Here? Dear MicroStrategy Stock Fans, Mark Your Calendars for July 31 2 Growth Stocks Wall Street Predicts Will Soar 74% to 159% Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Narrowing the focus, BMY has also underperformed the SPDR S&P Pharmaceuticals ETF's (XPH) 1.8% drop over the past 52 weeks and 2.2% loss on a YTD basis. On Jul. 31, BMY released its Q2 results. The company's top line grew marginally year-over-year to $12.3 billion. Lower legacy portfolio revenue was more than offset by higher sales in the growth portfolio. Meanwhile, on the earnings front, its adjusted EPS of $1.46 declined 29.5% from the year-ago quarter, whereas its adjusted net income fell 27.1% year-over-year, reaching $3.6 billion. Looking ahead to fiscal 2025, BMY raised its revenue guidance to a range of $46.5 billion to $47.5 billion, and updated its adjusted EPS outlook to be between $6.35 and $6.65. For the current fiscal year, ending in December, analysts expect BMY's EPS to grow by a notable 446.1% year over year to $6.28. The company's earnings surprise history is promising. It topped the consensus estimates in each of the last four quarters. Among the 26 analysts covering the stock, the consensus rating is a 'Moderate Buy' which is based on seven 'Strong Buy,' 18 "Hold,' and one "Strong Sell' rating. The configuration has remained consistent over the past three months. On Jul. 29, Carter Gould from Cantor Fitzgerald maintained a 'Hold' rating on BMY with a price target of $55, indicating a 19.6% potential upside from the current levels. The mean price target of $55.48 represents a 20.7% premium from BMY's current price levels, while the Street-high price target of $68 suggests an ambitious upside potential of 47.9%. On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
